Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Depression
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Depression
    Prediction of Long-Term Remission in Major Depressive Disorder Allows for Early Treatment Adjustments: Presented at ECNP - (DGDispatch)
    TopAbstracts in Depression 09/03/2008 - (DGNews)
    Brief, 3-Question Scale Effective in Uncovering Postpartum Depression - (DGNews)
    The ECNP Consensus Statement on Bipolar Depression - (DGNews)
    Montelukast Does Not Cause Depression or Suicide, American Lung Association Study Concludes - (DGNews)

    News archive

     Recent webcasts/CME - Depression
    Recognition and Management of Depression
    Understanding the Vital Link: Depression and Chronic Disease

    Webcasts/CME archive

     Recent cases - Depression
      A Postmenopausal Woman Presenting with Ekbom Syndrome Associated with Recurrent Depressive Disorder: A Case Report
      Affective Psychosis, Hashimoto's Thyroiditis, and Brain Perfusion Abnormalities: Case Report
      Dissecting the Determinants of Depressive Disorders Outcome: An in Depth Analysis of Two Clinical Cases
      Incomplete Oedipism and Chronic Suicidality in Psychotic Depression with Paranoid Delusions Related to Eyes
      Excessive Weight Gain after Remission of Depression in a Schizophrenic Patient Treated with Risperidone: Case Report

      Cases archive
        




      my personal edition > depression > news
      divider

        E-Mail this DGReview to a colleague

      DGReview


      Major Depression: Tianeptine At Least Halves Relapse And Recurrence Rates

      A DGReview of :"Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression"
      Human Psychopharmacology: Clinical and Experimental

      03/29/2001
      By Mark Greener


      In unipolar major depression, tianeptine reduces rates of relapse and recurrence by between two- and three-fold compared to placebo, report researchers from Université Claude-Bernard, in Lyon, and other French centres.

      They enrolled 268 patients who fulfilled Diagnostic and Statistical Manual Revision III criteria for major depression and who had Hamilton depression rating scale (HDRS) scores of at least 17 out of 21 and at least one episode of depression in the previous five years. Patients received tianeptine for six weeks in an open study.

      Of the 185 responders, 111 received tianeptine 37.5 mg daily, while 74 received placebo for 16.5 months. The authors defined relapse as occurring before six months and recurrences as occurring after six months. Patients were considered to have relapsed or experienced a recurrence if they had a HDRS score of at least 15, a clinical global impression score of at least 4 or both, and clinical confirmation by the investigator.

      The tianeptine and placebo groups were similar in most respects at baseline. However, the severity of the depressive episode was greater in the tianeptine group.

      A smaller proportion of the tianeptine group experienced either relapses or recurrences compared to placebo (16 and 36 percent, respectively). Moreover, the differences between tianeptine and placebo increased with a longer duration of follow-up. Several secondary analyses confirmed tianeptine's superiority. Adverse events related to treatment were rare and mild in both arms of the study.

      The authors conclude that their findings support tianeptine's use in the long-term treatment of unipolar major recurrent depression. The rates of relapse and recurrence decreased between two- and three-fold among tianeptine users compared to placebo. However, the treatments were equally well accepted by the two groups.
      Human Psychopharmacology 2001;16:S39-S47. "Efficacy of tianeptine vs placebo in the long-term treatment (16.5 months) of unipolar major recurrent depression"

      E-Mail this DGReview to a colleague   To print, use this version






      All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



      The NTK initiative. Physicians helping physicians identify Need-To-Know science
         Feedback
      Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
      Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
      1
      2
      3
      4
      5
      6
      7
      Send